SS-31 clinical trial results show mixed outcomes in mitochondrial disease and eye conditions. Here's what the research found, plus safety and dosing basics.
SS-31, also known as elamipretide, has been tested in several human clinical trials, but the results have been mixed. The peptide has been studied most extensively in Barth syndrome, primary mitochondrial myopathy, and dry age-related macular degeneration, and it is not FDA-approved for human use in the United States. No trial has yet produced the consistent, confirmatory benefit that would support routine clinical use.
What Is SS-31 and Why Is It Being Studied?
SS-31 is a synthetic tetrapeptide designed to concentrate inside mitochondria. Its chemical sequence is D-Arg-Dmt-Lys-Phe-NH2, and it has also appeared in the literature under the names elamipretide, MTP-131, Bendavia, and Forzinity.
The proposed mechanism is unusual. The peptide binds to cardiolipin on the inner mitochondrial membrane and appears to stabilize the electron transport chain. In laboratory models, that translates into lower reactive oxygen species production and better ATP output.
Whether those cellular changes produce meaningful benefit in people is exactly what the trials have been trying to determine. SS-31 is a research compound, not a dietary supplement and not an approved drug.
SS-31 Human Trials: What Has Actually Been Tested
Elamipretide has moved through Phase 1, Phase 2, and Phase 3 studies. The table below summarizes the main programs and how they turned out.
| Indication / Program | Route and Design | Reported Outcome |
|---|---|---|
| Barth syndrome (TAZPOWER) | Subcutaneous daily injection, Phase 3 | Missed the primary endpoint; some functional and cardiac measures favored treatment in secondary analyses. |
| Primary mitochondrial myopathy (MMPOWER-3) | Subcutaneous daily injection, Phase 3 | Missed the primary six-minute walk endpoint; secondary signals were inconsistent. |
| Dry age-related macular degeneration (ReCLAIM, ReCLAIM-2) | Subcutaneous daily injection | Phase 2 showed vision-related signals; the larger follow-up study did not confirm the primary endpoint. |
| Acute myocardial infarction and heart failure (EMBRACE STEMI and related studies) | Intravenous infusion | No clear benefit on infarct size or clinical outcomes. |
| Healthy older adults and exploratory studies | Various | Small effects on muscle energetics and exercise measures; sample sizes were too small for firm conclusions. |
The pattern is similar across programs. The peptide has generally been safe and tolerable, but large trials have not consistently hit their pre-specified endpoints.
Some researchers argue the endpoints were poorly chosen for rare, heterogeneous diseases. Critics counter that a therapy still has to show measurable benefit in the population being studied. Discussion of ss 31 human trials in the literature tends to return to that same unresolved point.
How SS-31 Is Dosed in Clinical Research
Route and dose have been fairly consistent across studies. In published protocols, ss-31 peptide dosing has been weight-based and delivered by subcutaneous injection, usually once daily.
- Phase 3 Barth syndrome and myopathy trials: roughly 0.25 mg/kg per day, subcutaneously.
- Earlier Phase 1 and Phase 2 work: dose escalation up to about 4 mg/kg per day in some protocols.
- Cardiac studies: intravenous infusion rather than injection.
Doses were not standardized across all programs, and there is no established human dose for any condition. Research vials sold online, such as ss-31 30mg, are laboratory supplies rather than clinical doses. Vial size tells you nothing about how the peptide should be used in a person.
SS-31 FDA Status and Regulatory Timeline
SS-31 is not FDA-approved for human use for any indication. The sponsor has pursued approval in Barth syndrome and has received orphan drug and rare pediatric disease designations, but the agency has issued complete response letters and an advisory committee has voted against approval.
Approval status can change, so verify the current label and review documents at FDA.gov instead of relying on forum posts. Questions about ss 31 fda status often trace back to headlines about those advisory committee meetings. A designation is not an approval, and an advisory committee vote is a recommendation, not a final decision.
Safety, Side Effects, and Open Questions
In completed trials, the most common complaints were injection-site reactions, headache, nausea, and fatigue. Investigators generally described ss 31 side effects as mild to moderate and reversible.
Important caveats remain:
- Long-term safety data beyond a few years are limited.
- Trials enrolled specific, often rare-disease populations, so results may not generalize to other groups.
- No human study has tested the peptide in combination with other research peptides. Some preclinical laboratories explore ss-31 and mots-c together in mitochondrial experiments, but that combination has no human safety or efficacy data.
Because there is no approved product, anyone asking where to buy ss-31 peptide is looking at research-grade material that is not manufactured under pharmaceutical standards and is not intended for human use. Sterility, purity, and accurate concentration cannot be assumed with these vials.
What the Evidence Means for Patients
The honest summary is that SS-31 clinical trial data are encouraging in mechanism and disappointing in confirmatory outcomes. That does not mean the compound is useless; it means the evidence is not yet strong enough to support clinical use outside a research setting.
Patients with mitochondrial disease who are interested in elamipretide should ask their specialist about open trials and expanded access programs rather than purchasing research vials. Talking with a healthcare professional before using any investigational peptide is the only reasonable way to weigh potential benefit against unknown risk.
Frequently Asked Questions
Has SS-31 been tested in humans?
Yes. Elamipretide has completed Phase 1, Phase 2, and Phase 3 human studies in Barth syndrome, primary mitochondrial myopathy, dry age-related macular degeneration, and cardiac conditions. Most of these trials reported acceptable tolerability but mixed efficacy results.
Is SS-31 FDA approved?
No. SS-31 is not FDA-approved for human use in the United States. The sponsor has received orphan drug and rare pediatric disease designations for Barth syndrome, but those designations are not approvals, and an FDA advisory committee has voted against approval. Check FDA.gov for the most current status.
What side effects showed up in SS-31 trials?
The most frequently reported side effects were injection-site reactions, headache, nausea, and fatigue, and investigators generally described them as mild to moderate. Long-term safety data remain limited, and no large trial has followed participants for many years after treatment.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.